A recent case control study demonstrated that serum and CSF levels of NfL protein were markedly higher in patients with symptomatic or presymptomatic (i.e., carriers) CSF1R-mutation-positive ALSP vs. that in healthy control subjects or in patients with MS (67). This evidence concerns the gene NEFL and myeloid sarcoma.